Fosphenytoin vs Rufinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Fosphenytoin
Marketed by Pfizer
NCT01960075 · Phase 3 · completed
This randomized, triple-blind phase 3 trial (ESETT) compared intravenous fosphenytoin, valproic acid and levetiracetam in 478 enrolments with benzodiazepine-refractory status epilepticus. The primary endpoint was clinical cessation of status epilepticus within 60 minutes. The trial stopped early for futility under a prespecified rule; in the intention-to-treat analysis of the first 400 patients, seizures stopped in 53 of 118 participants on fosphenytoin, 56 of 121 on valproic acid and 68 of 145 on levetiracetam, and no arm was shown to be superior.
No aligned efficacy figure on record for this race.
Rufinamide
Marketed by Eisai and partners
NCT00334958 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.
The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.
Reported efficacy
Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)
Result source: NCT00334958
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Fosphenytoin | Rufinamide |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00908453 | —Not reported |
| 50% responder rate | —Not posted · NCT00908453 | —Not reported |
| Seizure freedom | —Not posted · NCT00908453 | —Not reported |
Seizure frequency, % change
- Fosphenytoin
- —Not posted · NCT00908453
- Rufinamide
- —Not reported
50% responder rate
- Fosphenytoin
- —Not posted · NCT00908453
- Rufinamide
- —Not reported
Seizure freedom
- Fosphenytoin
- —Not posted · NCT00908453
- Rufinamide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Fosphenytoin: 3 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fosphenytoin | Rufinamide |
|---|---|---|
| Dropout rate | 38.2%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 21%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 24.1% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 15.3%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 12% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 7.4% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result22.2%400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 3.4%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results3.4% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 16.7% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a dizziness 9.2% fatigue 9.2% burning at the iv site 6.6% NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result400mg respiratory failure 6.7% acute respiratory failure 4.4% bradycardia 4.4% NCT01458522 · Phase 2 · registry result, not featured evidence | b dizziness 26.7% (placebo 8.3%) headache 16.5% (placebo 12.8%) fatigue 15.3% (placebo 10%) NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more resultsnasopharyngitis 31% (placebo 30%) status epilepticus 27.6% (placebo 16.7%) decreased appetite 20.7% (placebo 6.7%) NCT01146951 · Phase 3 · monotherapy upper respiratory tract infection 28% vomiting 28% somnolence 20% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 nasopharyngitis 48.1% status epilepticus 40.7% somnolence 25.9% NCT01151540 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fosphenytoin
Rufinamide
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fosphenytoin's landscape · Rufinamide's landscape